Circulars & Announcements
2021
Ascentage Pharma Announces Approval by NMPA for China’s First Approved Third-Generation
BCR-ABL TKI HQP1351 (Olverembatinib)
November 25, 2021
Ascentage Pharma’s core drug candidate HQP1351 (Olverembatinib) Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia
November 22, 2021
On-market Repurchase of Shares
November 11, 2021
Next Day Disclosure Return
November 11, 2021
On-market Repurchase of Shares
November 10, 2021
Next Day Disclosure Return
November 10, 2021
On-market Repurchase of Shares
November 9, 2021
Next Day Disclosure Return
November 9, 2021
Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4/6 Inhibitor IBRANCE® (Palbociclib) in the Treatment of Metastatic ER+/HER2- Breast Cancer
November 8, 2021
On-market Repurchase of Shares
November 8, 2021
Next Day Disclosure Return
November 8, 2021
On-market Repurchase of Shares
November 5, 2021
Next Day Disclosure Return
November 5, 2021
Abstracts on six studies of Ascentage Pharma’s three drug candidates under development (Olverembatinib, APG-2575, and APG-1252) have been
selected for oral presentation and poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting
November 5, 2021
Next Day Disclosure Return
November 4, 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October
November 4, 2021
On-market Repurchase of Shares
November 4, 2021
Resignation of Chief Financial Officer
November 1, 2021
Completion of the Issuance of Unlisted Warrants under Specific Mandate
October 12, 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September
October 7, 2021
Ascentage Pharma’s MDM2-p53 Inhibitor APG-115 Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma
September 23, 2021
Poll Results of the Extraordinary General Meeting Held on September 20,2021
September 20, 2021
(1) Disclosable Transactions — Subscription of Commercial Paper and Structured Financial Products and (2) Supplemental Announcement in relation to the 2021 Interim Report
September 10, 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August
September 6, 2021
Form of Proxy for the Extraordinary General Meeting to be Held on September 20, 2021
August 31, 2021
Notice Of Extraordinary General Meeting
August 31, 2021
Circular (1) Connected Transaction — Proposed Grant of RSUs to Connected Selected Persons;(2) Proposed Grant of RSU Specific Mandate to Issue Shares under the 2021 RSU scheme; (3) Proposed Grant of Warrant Specific Mandate to Issue Unlisted Warrants and Warrant Shares and (4) Notice of Extraordinary General Meeting
August 31, 2021
Retirement of Chief Operating Officer
August 30, 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July(Revised)
August 29, 2021
Announcement of Unaudited Interim Results for the Six Months Ended JUNE 30, 2021
August 24, 2021
Notice of Board Meeting
August 12, 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July
August 5, 2021
Delay in Despatch of Circular in relation to (1) Proposed Issuance of Unlisted Warrants under Specific Mandate; and (2) Connected Trsansactions — Proposed Grant of Awards under the 2021 RSU Scheme to Independent Non-executive Directors and Chief Commercial Officer
July 30, 2021
Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325
July 28, 2021
Connected Transaction Cancellation of Proposed Grant of Awards and Proposed Re-grant of Awards under the 2021 RSU Scheme to independent non-executive Directors
July 24, 2021
Next Day Disclosure Return
July 23, 2021
Ascentage Pharma’s MDM2-p53 Inhibitor, APG-115 (Alrizomadlin), Received an Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma
July 21, 2021
Ascentage Pharma Establishes Cooperation with the US National Cancer Institute to advance the Clinical Development of Ascentage Pharma’s Bcl-2/Bcl-xL inhibitor APG-1252
July 20, 2021
Inside Information – Entry Into of the HQP1351 Collaboration and License agreement and the APG2575 Combination Therapy Strategic Collaboration and Clinical Trial Agreement; Issuance of New Shares under General Mandate; and Proposed Issuance of Unlisted Warrants under Specific Mandate
July 14, 2021
Connected Transaction Proposed Grant of Awards under the 2021 RSU Scheme to Independent Non-executive Directors Appointment of Independent Financial Adviser
July 14, 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June
July 6, 2021
Next Day Disclosure Return
June 29, 2021
2020 Environmental, Social and Governance Report
June 29, 2021
CLARIFICATION ANNOUNCEMENT GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO THE INDEPENDENT SELECTED PERSONS
June 25, 2021
UPDATE ANNOUNCEMENT GRANT OF AWARDS UNDER THE 2021 RSU SCHEME
June 18, 2021
Ascentage Pharma Announces IND Clearance by the US FDA for APG2575 as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors
June 14, 2021
Ascentage Pharma Delivers Oral Presentation Featuring Updated Data Demonstrating Promising Efficacy and
Safety of APG-2575 in Patients with Relapsed or Refractory CLL/SLL; APG-115 Demonstrating Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs
June 8, 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2021
June 4, 2021
SUPPLEMENTAL ANNOUNCEMENT GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND CONNECTED TRANSACTION PROPOSED GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO CHIEF COMMERCIAL OFFICER AND INDEPENDENT NON-EXECUTIVE DIRECTOR
May 26, 2021
GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND CONNECTED TRANSACTION PROPOSED GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO CHIEF COMMERCIAL OFFICER
May 21, 2021
Ascentage Pharma to Announce Updated Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) Demonstrating an Objective Response Rate of Around 80% and Therapeutic Potential in Patients with R/R CLL/SLL in
Oral Presentation at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO)
May 20, 2021
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 10, 2021
May 10, 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2021
May 5, 2021
Ascentage Pharma to Announce Results from Four Clinical Studies at 2021 ASCO Annual Meeting, with Data of Two of Its Drug Candidates Including Lisaftoclax (APG-2575) to Be Released in Oral Presentations for the First Time
April 21, 2021
Presentation by Ascentage Pharma of Results of Latest Preclinical Studies at 2021 American Association for Cancer Research (AACR) Annual Meeting which Demonstrate Potential of Multiple Combination Therapies
April 13, 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021
April 9, 2021
CLARIFICATION ANNOUNCEMENT IN RELATION TO RESIGNATION OF NON-EXECUTIVE DIRECTOR AND
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
April 1, 2021
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2020
March 31, 2021
List of directors and their roles and functions
March 31, 2021
RESIGNATION OF NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR RESIGNATION OF NON-EXECUTIVE DIRECTOR
March 31, 2021
Ascentage Pharma’s First Third-Generation BCR-ABL Inhibitor in China Olverembatinib (HQP1351) Recommended for Breakthrough Therapy Designation
March 24, 2021
NOTICE OF BOARD MEETING
March 19, 2021
CLARIFICATION ANNOUNCEMENT IN RELATION TO GRANT OF AWARDS UNDER THE RSU SCHEME
March 19, 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021
March 5, 2021
Next Day Disclosure Return
February 11, 2021
CLOSING OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE
February 11, 2021
PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE
February 4, 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2021
February 3, 2021
Adoption of the 2021 RSU scheme
February 2, 2021
Voluntary Announcement -APG-2575 Granted the Fifth Orphan Drug Designation by the US FDA
January 29, 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020
January 6, 2021
Voluntary Announcement -Ascentage Pharma Obtained its 9th Orphan Drug Designation from the US FDA in 2020, Setting a Record among Chinese Biopharmaceutical Companies
January 5, 2021
2020
Voluntary Announcement -Received Milestone Payment for the Partnership with UNITY Biotechnology
December 22, 2020
Voluntary Announcement -Announcement of Updates on the Clinical Development of APG-2575, Including An Objective Response Rate of 70% in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
December 10, 2020
Voluntary Announcement -Positive Data from Pivotal Phase II Studies of HQP1351 (Olverembatinib) was Announced at 2020 American Society of Hematology Annual Meeting
December 8, 2020
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2020
December 3, 2020, 2020
Voluntary Announcement -Phase IIa Clinical Study of APG-115 as Single Agent or in Combination with APG-2575 Receives Clearances in China and the U.S.
December 2, 2020
Clarification Announcement
December 1, 2020
Voluntary Announcement -Entry into of an Agreement with the University of Michigan to Obtain An Exclusive License for a MDM2 Protein Degrader Using PROTACs Technology
November 30, 2020
Next Day Disclosure Return
November 25, 2020
Voluntary Announcement -APG-2575 Completed Dosing of the First Patient in Europe in Phase Ib/II Clinical Study
November 25, 2020
Voluntary Announcement -APG-2575 Receives Approvals for Two Phase Ib/II Clinical Studies in China
November 23, 2020
Voluntary Announcement -Ascentage Pharma Accepted for the Third Time to Release Updated Clinical Data of HQP1351 (Olverembatinib) in Drug-Resistant Chronic Myeloid Leukemia in an Oral Presentation at the American Society of Hematology Annual Meeting
November 9, 2020
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2020
November 4, 2020
Voluntary Announcement -APG-115 Granted Approval for the Phase Ib/II Clinical Study in China
October 27, 2020
Voluntary Announcement -Olverembatinib (HQP1351) of Ascentage Pharma is Included in the List of “Priority Review
October 21, 2020
Voluntary Announcement -APG-115 and APG-1252 Granted Orphan Drug Designation by the US FDA
October 9, 2020
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2020
October 7, 2020
Grant of Awards under the RSU Scheme
September 16, 2020
Voluntary Announcement -APG-115 Granted Orphan Drug Designation by the FDA for the Treatment of Gastric Cancer
September 14, 2020
2020 Interim Report
September 14, 2020
Voluntary Announcement -APG-2575 Granted Second Orphan Drug Designation by the US FDA
September 7, 2020
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2020
September 3, 2020
Announcement of Unaudited Interim Results for the Six Months Ended June 30,2020
August 18, 2020
Voluntary Announcement -Becoming A Constituent of the Hang Seng Family of Indexes
August 17, 2020
Notice of Board Meeting
August 6, 2020
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2020
August 5, 2020
Voluntary Announcement – APG-115 Completed Dosing of the First Patient in Phase Ib Clinical Study in China
July 22, 2020
Voluntary Announcement – APG-2575 Granted Orphan Drug Designation by the US FDA
July 15, 2020
Next Day Disclosure Return
July 15, 2020
Closing of Placing of New Shares under General Mandate
July 15, 2020
2019 Environmental, Social and Governance Report
July 13, 2020
Placing of New Shares under General Mandate
July 8, 2020
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2020
July 6, 2020
Voluntary Announcement – Clinical Collaboration with MSD
July 6, 2020
Voluntary Announcement – Clinical Collaboration with Acerta Pharma, the Hematology Research and Development Center of Excellence of AstraZeneca
June 22, 2020
Poll Results of the Annual General Meeting Held on June 19, 2020
June 19, 2020
Voluntary Announcement – Submission of New Drug Application for HQP1351 in China
June 18, 2020
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2020
June 3, 2020
Voluntary Announcement – Latest Clinical Data of Apoptosis Targeting Drug Candidates was Presented at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2020
Voluntary Announcement – HQP1351 Granted Fast Track Designation by the US FDA
May 7, 2020
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2020
May 6, 2020
Voluntary Announcement – HQP1351 Granted Orphan Drug Designation by the U.S. FDA
May 4, 2020
Form of Proxy for the Annual General Meeting to Be Held on June 19, 2020
April 17, 2020
Notice of Annual General Meeting
April 17, 2020
2019 Annual Report
April 17, 2020
Proposed Re-election of Retiring Directors and Proposed Granting of General Mandates to Issue Shares and Repurchase Shares and Notice of Annual General Meeting
April 17, 2020
Voluntary Announcement – Approval for the Phase Ib/II Clinical Study of APG-2575 in China
April 7, 2020
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2020
April 6, 2020
Announcement of Annual Results for the Year Ended December 31, 2019
March 29, 2020
Voluntary Announcement – APG-2575 completed dosing of first patient in Phase Ib/II trial in the U.S.
March 23, 2020
Notice of Board Meeting
March 12, 2020
Voluntary Announcement – Approvals obtained in China and U.S. for three phase Ib/II clinical trials of APG-2575
March 9, 2020
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2020
March 4, 2020
Voluntary Announcement – Approval of phase Ib/II clinical trial of APG-1387 for the treatment of advanced pancreatic cancer in combination with chemotherapy in China
February 24, 2020
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2020
February 6, 2020
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2019
January 3, 2020
Voluntary Announcenment – Studies of HQP1351 nominated the “Best of ASH” at the 2019 American Society of Hematology Annual MeetingDecember 11, 2019 |
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2019December 4, 2019 |
Next Day Disclosure ReturnNovember 25, 2019 |
FULL EXERCISE OF THE OVER-ALLOTMENT OPTION,STABILISING ACTIONS AND END OF STABILISATION PERIODNovember 21, 2019 |
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2019November 06, 2019 |
Amended and Restated Memorandum and Articles of AssociationOctober 25, 2019 |
Terms of Reference for Nomination CommitteeOctober 25, 2019 |
Terms of Reference for Audit CommitteeOctober 25, 2019 |
Terms of Reference for Remuneration CommitteeOctober 25, 2019 |
List of Directors and their Roles and FunctionsOctober 25, 2019 |
Procedures for election as directorOctober 25, 2019 |
Board Diversity policyOctober 25, 2019 |
Shareholders Communication PolicyOctober 25, 2019 |
Global Offering – Allotment ResultsOctober 25, 2019 |